A Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Trial to Assess the Effects of 4 g/d P-OM3 on LDL-C and Other Aspects of the Fasting Lipid Profile in Subjects With Primary Hypercholesterolemia.

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Trial to Assess the Effects of 4 g/d P-OM3 on LDL-C and Other Aspects of the Fasting Lipid Profile in Subjects With Primary Hypercholesterolemia.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Omega-3-acid ethyl esters (Primary)
  • Indications Hypercholesterolaemia
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 29 Jan 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 23 Sep 2009 Planned initiation date changed from 1 Jul 2009 to 1 Jan 2010 as reported by ClinicalTrials.gov.
    • 23 Sep 2009 Planned end date changed from 1 Mar 2010 to 1 Oct 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top